

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2020 P 3107-3
Program	Step Therapy
Medication	Solosec (secnidazole)
P&T Approval Date	4/2018, 3/2019, 3/2020
Effective Date	6/1/2020; Oxford only: 6/1/2020

1. Background:

Solosec (secnidazole) is indicated for the treatment of bacterial vaginosis. Solosec is available as a two gram oral granule and should be taken as a single dose.

Step therapy programs are intended to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try an alternative antibacterial agent before providing coverage for Solosec.

2. Coverage Criteria^a:

A. Initial Authorization

1. Solosec will be approved based on the following criterion:

a. History of failure, contraindication or intolerance to **one** of following:

- 1) clindamycin capsules (generic Cleocin)
- 2) clindamycin vaginal cream (generic Cleocin, Clindesse)
- 3) clindamycin vaginal suppository (Cleocin)
- 4) metronidazole tablets (generic Flagyl)
- 5) metronidazole vaginal gel (Metrogel-Vaginal)
- 6) tinidazole tablets (generic Tindamax)

Authorization will be issued for one month.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place

4. References:

1. Solosec [package insert]. Baltimore, MD: Lupin Pharmaceuticals, Inc.; October 2019.
2. 2015 Sexually Transmitted Diseases Treatment Guidelines. Bacterial Vaginosis. Centers for Disease Control and Prevention. June 2015.

Program	Step Therapy – Solosec
Change Control	
Date	Change
4/2018	New program.
3/2019	Annual review. Added Cleocin vaginal suppositories as a step 1 agent. Added statement regarding use of automated process.
3/2020	Annual review. Updated references.